Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Angiodynamics › Point72 Asset Management, L.P. cut its ANGO stake below 5% (2.3%) Fund moves
Why it stands out The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 16, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0000919574-26-008102
Data quality Verified: identifiers matched exactly
Around the same time Insider filing
Traded Nov 2 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 2 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 2 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
What came next Oct 2, 2026 Company filing · Form 8-K · Material agreement, Executive change Changed a top executive or board member, and signed an important agreement “On October 2, 2026, the Board of Directors of the Company (the “ Board ”) appointed Eric Honroth to serve as President and Chief Executive Officer of the Company, effective as of November 2, 2026 (the “ Effective Date ”) and concurrently with Mr. Clemmer’s retirement.” Oct 8, 2026 Company filing · Form 8-K · Results, Reg FD Reported its results, and shared information with investors Oct 28, 2026 Insider CFO sold ~$21K of ANGO shares in the open market Oct 29, 2026 Insider CFO sold ~$290K of ANGO shares in the open market Oct 30, 2026 FDA FDA device clearance: AngioVac F1885 Nov 16, 2026 5% stake Point72 Asset Management, L.P. reported a passive stake (13G) of 2.3% Nov 18, 2026 Company filing · Form 8-K · Executive change, Shareholder vote Changed a top executive or board member, and held a shareholder vote “(e) As described below, the shareholders of AngioDynamics, Inc. (“AngioDynamics”) voted on November 17, 2026 to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan (the “2020 Plan”) to increase the number of shares available for issuance.”